Vimarsana
Biggest News Aggregation in the World

Polypid News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Polypid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Polypid Today - Breaking & Trending Today

PolyPid (NASDAQ:PYPD) Given Buy Rating at HC Wainwright - Vimarsana News

PolyPid (NASDAQ:PYPD) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of PolyPid (NASDAQ:PYPD – Free Report) in a research note published on Wednesday, Benzinga reports. They currently have a $14.00 target price on the stock. HC Wainwright also issued estimates for PolyPid’s Q1 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($0.77) EPS, Q3 2025 earnings […]

Source: wkrb13.com
PolyPid (NASDAQ:PYPD) Earns "Buy" Rating from HC Wainwright - Vimarsana News

PolyPid (NASDAQ:PYPD) Earns "Buy" Rating from HC Wainwright

HC Wainwright reiterated their buy rating on shares of PolyPid (NASDAQ:PYPD – Free Report) in a research report sent to investors on Wednesday, Benzinga reports. The brokerage currently has a $14.00 target price on the stock. HC Wainwright also issued estimates for PolyPid’s Q1 2025 earnings at ($0.81) EPS, Q2 2025 earnings at ($0.77) EPS, […]

PolyPid (NASDAQ:PYPD) vs. LeMaitre Vascular (NASDAQ:LMAT) Head-To-Head Comparison - Vimarsana News

PolyPid (NASDAQ:PYPD) vs. LeMaitre Vascular (NASDAQ:LMAT) Head-To-Head Comparison

PolyPid (NASDAQ:PYPD – Get Free Report) and LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, institutional ownership, dividends, analyst recommendations, profitability, risk and earnings. Earnings and Valuation This table compares PolyPid and […]

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results - Vimarsana News

PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results

More Than 100 Patients Enrolled in Ongoing SHIELD II Phase 3 Trial of D-PLEX100 for the Prevention of Abdominal Colorectal Surgical Site Infections Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 New Preclinical Data Showed OncoPLEX Injected Intratumorally Reduced Tumor Volume and Improved Survival in New Animal Models Recent Successful $16 Million Financing Extends Company’s Cash Runway

Source: yahoo.com
Financial Survey: PolyPid (NASDAQ:PYPD) and Assure (NASDAQ:IONM) - Vimarsana News

Financial Survey: PolyPid (NASDAQ:PYPD) and Assure (NASDAQ:IONM)

PolyPid (NASDAQ:PYPD – Get Free Report) and Assure (NASDAQ:IONM – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings. Risk and Volatility PolyPid has a beta of 1.45, […]